Literature DB >> 6245301

Naturally occurring leukemia viruses in H-2 congenic C57BL mice. I. High lymphoma incidence following milk-borne transmission of virus.

C J Melief, A Vlug, R E de Goede, C de Bruyne, W Barendsen, P de Greeve.   

Abstract

Two modes of transmission of ecotropic type C viruses occur naturally in C57BL mice: maternal (i.e., through milk) and genetic. By selection of virus-positive and virus-negative B10.ASgSn [B10.A (H-2a)] mothers and foster-nursing of C57BL/10ScSn [B10 (H-2b)] newborns, four sublines of C57BL mice were obtained: B10.A V+, B10.A V-, B10 V+, and B10 V-. (V+ denotes positive for milk-transmitted B-tropic virus; V- denotes negative for milk-transmitted B-tropic virus). Milk transmission of naturally prevalent B-tropic virus (V+ sublines) led to persistent infection of all offspring over at least 8 generations. Milk transmission of virus was associated with a very high incidence of lymphomas. The H-2 complex influenced the titers of virus after milk transmission, which were higher in B10.A V+ mice than in B10 V+ mice. H-2 control of virus titers, as measured by serum p30 assay, was confirmed in (B10.A V+ X B10 V+)F2 mice. Resistance to the virus was dominant, because serum p30 levels in F1 and H-2a/b F2 animals were similar to those in the B10 V+ subline and lower than those in the B10.A V+ subline. The H-2 complex also influenced the incidence of lymphomas (78 and 42%, respectively, in the B10.A V+ and B10 V+ sublines). Most B10.A V+ lymphomas were of T-cell origin, whereas most B10 V+ lymphomas were classified as non-T/non-B cells. Genetic transmission of virus (V- sublines) led to heterogeneous expression of both N- and B-tropic viruses, which thereby established the mottled trait for expression of genetically transmitted type C viruses in C57BL mice. Genetic transmission was associated with a low incidence of lymphomas that occurred in senescence.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245301

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  8 in total

1.  Ecotropic and mink cell focus-forming murine leukemia viruses integrate in mouse T, B, and non-T/non-B cell lymphoma DNA.

Authors:  M Zijlstra; W Quint; T Cuypers; T Radaszkiewicz; H Schoenmakers; R de Goede; C Melief
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

2.  Major histocompatibility complex class II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas.

Authors:  W L Vasmel; M Zijlstra; T Radaszkiewicz; C J Leupers; R E de Goede; C J Melief
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

3.  Transplacental transmission of a leukemogenic murine leukemia virus.

Authors:  H G Bedigian; L A Shepel; P C Hoppe
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

4.  Naturally occurring cytotoxic human antibodies recognize H-2-controlled murine lymphocyte antigens.

Authors:  P Iványi; T Leupers; P van Mourik
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

5.  Major histocompatibility complex heterozygote superiority during coinfection.

Authors:  Erin E McClelland; Dustin J Penn; Wayne K Potts
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

6.  Primary virus-induced lymphomas evade T cell immunity by failure to express viral antigens.

Authors:  W L Vasmel; E J Sijts; C J Leupers; E A Matthews; C J Melief
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

7.  Involvement of c-myc in MuLV-induced T cell lymphomas in mice: frequency and mechanisms of activation.

Authors:  G Selten; H T Cuypers; M Zijlstra; C Melief; A Berns
Journal:  EMBO J       Date:  1984-12-20       Impact factor: 11.598

8.  Imbalanced MHC class II molecule expression at surface of murine B cell lymphomas.

Authors:  M Zijlstra; W L Vasmel; M Voormanns; R E de Goede; H J Schoenmakers; J Nieland; R M Slater; C J Melief
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.